Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Authorized symbols : Lly save search
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
Published: 2021-12-03 (Crawled : 22:00) - biospace.com/
ABCL | $4.01 1.01% 1M
|
|
| O: 3.41%
H: 0.0%
C: 0.0%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 2.15%
H: 0.0%
C: 0.0%
covid therapy authorized antibody merge
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
Published: 2021-12-03 (Crawled : 20:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.515 -0.7% 4.3M
|
Health Technology
| Email alert
Add to watchlist
covid therapy authorized antibody merge
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
| Email alert
Add to watchlist
covid expansion merge authorized emergency use authorization
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
JNJ | News | $148.515 -0.7% 4.3M
|
Health Technology
|
| O: 0.14%
H: 0.49%
C: -0.26%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid merge authorized emergency use authorization
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
Published: 2021-09-16 (Crawled : 22:00) - biospace.com/
ABCL | $4.01 1.01% 1M
|
|
| O: -0.11%
H: 5.8%
C: 5.38%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.15%
H: 0.26%
C: -1.3%
covid fda merge authorized emergency use authorization
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
Published: 2021-05-26 (Crawled : 23:00) - globenewswire.com
GSK | News | $40.905 -0.81% 890K
|
Health Technology
|
| O: -0.8%
H: 0.69%
C: 0.23%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
VIR | $8.205 0.92% 240K
|
Health Technology
|
| O: 4.2%
H: 0.3%
C: -9.4%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid treatment fda risk biotech technology iot merge authorized emergency use authorization
Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization
Published: 2021-05-03 (Crawled : 20:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.87%
H: 1.36%
C: 0.36%
authorized
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Published: 2021-04-16 (Crawled : 11:00) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.79%
H: 1.56%
C: 1.0%
covid treatment merge authorized emergency use authorization
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
Published: 2021-03-26 (Crawled : 13:00) - globenewswire.com
GSK | News | $40.905 -0.81% 890K
|
Health Technology
|
| O: -0.28%
H: 2.0%
C: 1.95%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 0.52%
H: 1.01%
C: 0.68%
VIR | $8.205 0.92% 240K
|
Health Technology
|
| O: 1.27%
H: 1.56%
C: -3.45%
SNY | News | $46.765 -1.94% 950K
|
Health Technology
|
| O: -0.31%
H: 1.33%
C: 1.22%
covid treatment fda biotech technology iot merge submission authorized emergency use authorization
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 08:00) - globenewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda merge authorized covid-19 emergency use authorization
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
Published: 2021-02-10 (Crawled : 07:00) - biospace.com/
ABCL | $4.01 1.01% 1M
|
|
| O: 12.77%
H: 0.06%
C: -11.34%
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda antibody merge authorized covid-19 emergency use authorization
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
Published: 2021-02-10 (Crawled : 01:15) - prnewswire.com
LLY | News | $735.1 -1.42% 1.2M
|
Health Technology
|
| O: 1.37%
H: 0.53%
C: -0.04%
covid fda merge authorized emergency use authorization
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.85 51.79% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
SKIL 4 | $8.045 40.89% 230K
|
Information
MULN | News | $3.805 39.38% 11M
|
Information
RILY | $30.01 38.17% 11M
|
Finance
MTC | $3.04 35.71% 6.7M
|
Technology Services
Your saved searches
Save your searches and get alerts when important news are released.